Clinical Trial

Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II, prospective clinical study to evaluate the efficacy and safety of Orelabrutinib combined with Low-Dose Radiotherapy or Rituximab in the treatment of Ocular Adnexal MALT Lymphoma
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07247383
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Marginal Zone Lymphoma of Ocular Adnexal, Marginal Zone Lymphoma(MZL)
Enrollment 39 participants
Start Date 2025-09-19
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-25